Changes in Hong Kong stocks | Minimally Invasive Xintong-B (02160) rose more than 10%. Annual TAVI product implantation volume increased by nearly 350% year-on-year

The Zhitong Finance App learned that Minimally Invasive Xintong-B (02160) rose by more than 10%. As of press release, it had risen 8.7% to HK$1.25, with a turnover of HK$11.482,800.

According to the news, Minimally Invasive Heart Connect recently announced. So far, the Group's VitaFow series transcatheter aortic valve and delivery system has entered 35 countries and regions around the world, with a cumulative total of nearly 1,300 implants. Among them, the number of implants is expected to exceed 850 in 2025, an increase of nearly 350% over 2024. The number of implants in the second half of 2025 increased by more than 170% compared to the first half of the year.

Notably, on December 21, the company announced the completion of a strategic merger with Minimally Invasive Heart Rate Management. CITIC Construction Investment said that by strategically integrating the heart rhythm management business of the Minimally Invasive Group, the company has broken through its dependence on a single track for structural heart disease and greatly enhanced the company's resilience to risks; at the same time, Xintong was able to obtain a more mature global sales network, further accelerating the company's overseas market expansion. In the future, Minimally Invasive Heart Connect is expected to combine the research and development technology accumulated by both parties in the field of medical devices to create a global professional device platform for the diagnosis and treatment of heart failure.